PRESS RELEASE published on 06/06/2024 at 07:30, 3 months 12 days ago Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
PRESS RELEASE published on 06/06/2024 at 07:30, 3 months 12 days ago Theranexus et BBDF confirment les résultats positifs à 18 mois de Batten-1 dans l'étude de phase 1/2 sur les neurofilaments, un biomarqueur de la mort neuronale Theranexus et BBDF confirment les résultats positifs à 18 mois de l'étude de phase 1/2 sur les neurofilaments, biomarqueur de la mort neuronale, concernant le médicament Batten-1 dans la maladie de Batten (CLN3) Theranexus Batten-1 Maladie De Batten BBDF Neurofilaments
BRIEF published on 05/02/2024 at 07:35, 4 months 16 days ago Theranexus unveils its universal registration document for 2023 2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF published on 05/02/2024 at 07:35, 4 months 16 days ago Theranexus dévoile son document d'enregistrement universel pour 2023 2023 Biopharmaceutique Document D'Enregistrement Universel Theranexus Maladies Neurologiques Rares
PRESS RELEASE published on 05/02/2024 at 07:30, 4 months 16 days ago MISE A DISPOSITION DU DOCUMENT D'ENREGISTREMENT UNIVERSEL 2023 Theranexus annonce le dépôt de son document d'enregistrement universel pour l'exercice 2023, disponible sur son site. Theranexus se spécialise dans le traitement des maladies neurologiques rares Biopharmaceutique Theranexus Maladies Neurologiques Rares Dépôt Document D'enregistrement Universel Neurones Et Cellules Gliales
BRIEF published on 04/29/2024 at 18:25, 4 months 19 days ago Theranexus publie ses résultats annuels 2023 et détaille ses progrès récents Résultats Financiers 2023 Theranexus Maladies Neurologiques Rares Maladie Des Lattes Projet PickASO
BRIEF published on 04/29/2024 at 18:25, 4 months 19 days ago Theranexus Reports 2023 Full-Year Results and Details Recent Progress 2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
PRESS RELEASE published on 04/29/2024 at 18:20, 4 months 19 days ago THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF published on 04/29/2024 at 18:05, 4 months 19 days ago Theranexus announces its 2023 annual results and the progress of its projects Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
BRIEF published on 04/29/2024 at 18:05, 4 months 19 days ago Theranexus annonce ses résultats annuels 2023 et les avancées de ses projets Biotechnologie Résultats Financiers 2023 Maladies Rares Theranexus Phase De Recherche
Published on 09/18/2024 at 23:10, 3 hours 42 minutes ago Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Published on 09/18/2024 at 23:00, 3 hours 52 minutes ago Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Published on 09/18/2024 at 21:15, 5 hours 37 minutes ago New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Published on 09/18/2024 at 21:00, 5 hours 52 minutes ago Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Published on 09/18/2024 at 16:30, 10 hours 22 minutes ago Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Published on 09/18/2024 at 19:11, 7 hours 41 minutes ago EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Published on 09/18/2024 at 18:45, 8 hours 7 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/18/2024 at 18:31, 8 hours 20 minutes ago EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Published on 09/18/2024 at 18:13, 8 hours 39 minutes ago BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Published on 09/18/2024 at 17:21, 9 hours 30 minutes ago EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Published on 09/18/2024 at 18:45, 8 hours 6 minutes ago Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Published on 09/18/2024 at 18:45, 8 hours 6 minutes ago Capital increase following the allocation of free shares to EuropaCorp employees
Published on 09/18/2024 at 17:40, 9 hours 12 minutes ago Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.